U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3842
    +0.0058 (+0.42%)
     
  • USD/JPY

    108.7500
    +0.0340 (+0.03%)
     
  • BTC-USD

    61,474.98
    -1,779.09 (-2.81%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Viemed Healthcare Announces Record 2020 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
Viemed Healthcare, Inc.
·17 min read
  • Oops!
    Something went wrong.
    Please try again later.

LAFAYETTE, La., March 03, 2021 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX: VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it has reported its financial results for the three months and year ended December 31, 2020.

Operational highlights (all dollar amounts are USD):

  • Net revenues attributable to the Company's core business for the quarter ended December 31, 2020 were $26.1 million, an increase of 22% over net revenues reported for the quarter ended December 31, 2019. Net revenues attributable to the Company's core business for the quarter ended December 31, 2020 were up approximately 5% over the quarter ended September 30, 2020. Total revenues for the current quarter were $31.2 million which included approximately $5.1 million of product sales and services related to the COVID-19 pandemic. Net revenues for the year ended December 31, 2020 were $96.9 million for the Company's core business and $131.3 million for the Company, including COVID-19 related sales and services.

  • Net income for the quarter ended December 31, 2020 totaled approximately $5.1 million, compared to $2.4 million for the quarter ended December 31, 2019. Net income for the year ended December 31, 2020 totaled approximately $31.5 million, compared to $8.5 million for the year ended December 31, 2019.

  • Adjusted EBITDA for the quarter ended December 31, 2020 totaled approximately $9.5 million, a 70% increase as compared to the quarter ended December 31, 2019. Adjusted EBITDA for the year ended December 31, 2020 totaled approximately $41.3 million, a 117% increase as compared to the year ended December 31, 2019. A reconciliation of reported non-GAAP financial measures to their most directly comparable U.S. GAAP financial measures can be found in the tables accompanying this press release.

  • The Company had a cash balance of $31.0 million at December 31, 2020 ($13.4 million at December 31, 2019) and an overall working capital balance of $24.2 million ($1.9 million at December 31, 2019). Total long-term debt as of December 31, 2020 was $6.6 million.

  • The Company expects to generate net revenues attributable to its core business of approximately $25.5 million to $26.5 million during the first quarter of 2021. In addition to its core business, the Company is continuing to pursue additional revenues related to the COVID-19 pandemic and estimates first quarter 2021 revenues of approximately $2.3 million to $3.3 million related to the COVID-19 pandemic. Total revenues for the first quarter of 2021 are estimated to be approximately $27.8 million to $29.8 million.

“I am extremely proud of the performance of our team during one of the most challenging years for the US healthcare system,” said Casey Hoyt, Viemed's CEO. “The pandemic posed more tailwinds than headwinds for us, which resulted in a record year for Viemed. We expect to continue to serve as a resource to our patients, physicians, and payors who continue to yearn for additional safe remote homecare solutions. We also remain optimistic about the strategic partnerships, organic growth, and acquisition opportunities that we expect to contribute to our expansion in 2021.”

Conference Call Details

The Company will host a conference call to discuss fourth quarter results on Wednesday, March 3, 2021 at 11:00 a.m. EST.

The call-in numbers for participants are:

US Toll Free Dial In: 1-877-407-0784
International Toll Free Dial In: 1-201-689-8560
Meeting ID Number: 13716960
Live Event Call me™ Link (Available 15 minutes prior to start time for participant entry)
https://callme.viavid.com/?callme=true&passcode=13707099&h=true&info=company-email&r=true&B=6

Following the conclusion of the call, an audio recording and transcript of the call can be accessed on the Company's website.

ABOUT VIEMED HEALTHCARE, INC.

Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Visit our website at www.viemed.com.

For further information, please contact:

Glen Akselrod
Bristol Capital
905-326-1888
glen@bristolir.com

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
investorinfo@viemed.com

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, or “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's net revenue guidance for the first quarter, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on the Company's patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the Company’s novel business model; the risk that the clinical application of treatments that demonstrate positive results in a study may not be positively replicated or that such test results may not be predictive of actual treatment results or may not result in the adoption of such treatments by providers; the state of the capital markets; the availability of funds and resources to pursue operations; decline of reimbursement rates; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; low profit market segments; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at www.sec.gov, including the Company’s most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at www.sedar.com. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.


VIEMED HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except share amounts)

At
December 31, 2020

At
December 31, 2019

ASSETS

Current assets

Cash and cash equivalents

$

30,981

$

13,355

Accounts receivable, net of allowance for doubtful accounts of $9,013 and
$7,782 at December 31, 2020 and December 31, 2019, respectively

12,373

11,534

Inventory, net of inventory reserve of $1,353 and $0 at December 31, 2020 and
December 31, 2019, respectively

2,310

1,360

Prepaid expenses and other assets

1,511

1,562

Total current assets

$

47,175

$

27,811

Long-term assets

Property and equipment, net

55,056

54,772

Equity method investment

733

13

Deferred tax asset

8,733

Other long-term assets

863

Total long-term assets

65,385

54,785

TOTAL ASSETS

$

112,560

$

82,596

LIABILITIES

Current liabilities

Trade payables

$

2,096

$

4,700

Deferred revenue

3,409

3,315

Income taxes payable

340

86

Accrued liabilities

12,595

8,968

Current portion of lease liabilities

2,741

7,093

Current portion of long-term debt

1,836

1,750

Total current liabilities

$

23,017

$

25,912

Long-term liabilities

Accrued liabilities

1,292

2,317

Long-term lease liabilities

762

3,039

Long-term debt

5,796

7,629

Total long-term liabilities

$

7,850

$

12,985

TOTAL LIABILITIES

$

30,867

$

38,897

Commitments and Contingencies

SHAREHOLDERS' EQUITY

Common stock - No par value: unlimited authorized; 39,185,182 and
37,952,660 issued and outstanding as of December 31, 2020 and December
31, 2019, respectively

9,181

3,366

Additional paid-in capital

7,320

6,377

Accumulated other comprehensive loss

(451

)

(157

)

Retained earnings

65,643

34,113

TOTAL SHAREHOLDERS' EQUITY

$

81,693

$

43,699

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

112,560

$

82,596


VIEMED HEALTHCARE, INC.
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except outstanding shares and per share amounts)

Three Months Ended
December 31,

Year Ended
December 31,

2020

2019

2020

2019

Revenue

$

31,202

$

21,448

$

131,309

$

80,256

Cost of revenue

12,024

7,205

51,198

24,250

Gross profit

$

19,178

$

14,243

$

80,111

$

56,006

Operating expenses

Selling, general and administrative

12,274

10,174

52,829

41,381

Research and development

395

203

1,083

848

Stock-based compensation

1,301

908

4,882

3,886

Depreciation

204

211

816

671

Loss (gain) on disposal of property and equipment

96

52

(2,328

)

360

Other (income) expense

(359

)

4

(3,952

)

3

Income from operations

$

5,267

$

2,691

$

26,781

$

8,857

Non-operating expenses

Unrealized gain on warrant conversion liability

(363

)

(Gain) loss from equity investments

(55

)

33

(91

)

110

Interest expense, net of interest income

100

212

509

314

Net income before taxes

5,222

2,446

26,363

8,796

Provision (benefit) for income taxes

151

58

(5,167

)

271

Net income

$

5,071

$

2,388

$

31,530

$

8,525

Other comprehensive income

Change in unrealized gain (loss) on derivative instruments, net of tax

27

79

(294

)

(157

)

Other comprehensive income (loss)

$

27

$

79

$

(294

)

$

(157

)

Comprehensive income

$

5,098

$

2,467

$

31,236

$

8,368

Net income per share

Basic

$

0.13

$

0.06

$

0.81

$

0.23

Diluted

$

0.12

$

0.06

$

0.78

$

0.21

Weighted average number of common shares outstanding:

Basic

39,161,215

37,952,660

38,743,516

37,716,864

Diluted

41,043,419

40,148,149

40,525,737

39,747,509


VIEMED HEALTHCARE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)

Year Ended December 31,

2020

2019

Cash flows from operating activities

Net income

$

31,530

$

8,525

Adjustments for:

Depreciation

9,582

6,400

Change in allowance for doubtful accounts

9,116

9,811

Change in inventory reserve

1,353

Share-based compensation

4,882

3,886

Unrealized gain on warrant conversion liability

(363

)

(Gain) loss on equity investments

(91

)

110

(Gain) loss on disposal of property and equipment

(2,328

)

360

Deferred income taxes (benefit)

(8,733

)

Net change in working capital

Increase in accounts receivable

(9,955

)

(12,506

)

Increase in inventory

(2,303

)

(306

)

Increase in prepaid expenses and other assets

(812

)

(733

)

Increase in trade payables

213

783

Increase in deferred revenue

94

725

Increase in accrued liabilities

2,308

2,461

Increase (decrease) in income tax payable

254

(66

)

Net cash provided by operating activities

$

35,110

$

19,087

Cash flows from investing activities

Purchase of property and equipment

(13,044

)

(13,385

)

Investment in equity investments

(629

)

Proceeds from sale of property and equipment

5,258

574

Net cash used in investing activities

$

(8,415

)

$

(12,811

)

Cash flows from financing activities

Proceeds from exercise of options

1,876

136

Proceeds from exercise of warrants

260

(Principal payments) net proceeds on notes payable

(142

)

4,446

(Principal payments) net proceeds on term note

(1,605

)

4,933

Shares repurchased and canceled under the Normal Course Issuer Bid

(1,522

)

Repayments of lease liabilities

(9,198

)

(11,587

)

Net cash used in financing activities

$

(9,069

)

$

(3,334

)

Net increase in cash and cash equivalents

17,626

2,942

Cash and cash equivalents at beginning of year

13,355

10,413

Cash and cash equivalents at end of period

$

30,981

$

13,355

Supplemental disclosures of cash flow information

Cash paid during the period for interest

$

559

$

333

Cash paid during the period for income taxes, net of refunds received

$

3,311

$

338

Supplemental disclosures of non-cash transactions

Property and equipment financed through finance leases

$

3,002

$

12,011

Property and equipment financed through leases under FASB ASC 842

$

57

$

615


Non-GAAP Financial Measures

This press release refers to “Adjusted EBITDA” which is a non-GAAP financial measure that does not have a standardized meaning prescribed by U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies. Adjusted EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, unrealized (gain) loss on warrant conversion liability and stock-based compensation. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. The following table is a reconciliation of net income (loss), the most directly comparable U.S. GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:


VIEMED HEALTHCARE, INC.
Reconciliation of Net Income to Non-GAAP Adjusted EBITDA
(Expressed in thousands of U.S. Dollars)
(Unaudited)

For the quarter ended

December 31,
2020

September 30,
2020

June 30,
2020

March 31,
2020

December 31,
2019

September 30,
2019

June 30,
2019

March 31,
2019

Net Income

$

5,071

$

2,804

$

19,412

$

4,243

$

2,388

$

2,853

$

1,326

$

1,958

Add back:

Depreciation

2,835

2,425

2,190

2,130

2,003

1,659

1,444

1,295

Interest expense

100

116

135

158

212

56

20

26

Unrealized (gain) loss on
warrant conversion liability

(800

)

268

169

Stock-based compensation

1,301

1,234

1,196

1,151

908

1,064

1,034

880

Income tax expense (benefit)

151

1,141

(6,646

)

187

58

51

24

138

Adjusted EBITDA

$

9,458

$

7,720

$

16,287

$

7,869

$

5,569

$

4,883

$

4,116

$

4,466



Year Ended
December 31, 2020

Net Income

$

31,530

Add back:

Depreciation

9,580

Interest expense

509

Stock-based compensation

4,882

Income tax expense (benefit)

(5,167

)

Adjusted EBITDA

$

41,334


Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. It is not a measurement of the Company’s financial performance under U.S. GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with U.S. GAAP and may not be comparable to other similarly titled measures of other businesses. Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of the Company’s operating results as reported under U.S. GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters the Company considers not to be indicative of ongoing operations; and other companies in the Company’s industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.


VIEMED HEALTHCARE, INC.
Key Financial and Operational Information
(Expressed in thousands of U.S. Dollars, except vent patients)
(Unaudited)

For the quarter ended

December 31,
2020

September 30,
2020

June 30,
2020

March 31,
2020

December 31,
2019

September 30,
2019

June 30,
2019

March 31,
2019

Financial Information:

Revenue

$

31,202

$

33,447

$

42,854

$

23,806

$

21,448

$

20,368

$

20,325

$

18,115

Gross Profit

19,178

19,453

25,927

15,553

14,243

14,050

14,639

13,074

Gross Profit %

61

%

58

%

61

%

65

%

66

%

69

%

72

%

72

%

Net Income

5,071

2,804

19,412

4,243

2,388

2,853

1,326

1,958

Cash (As of)

30,981

32,396

29,707

8,409

13,355

12,630

7,691

7,410

Total Assets (As of)

112,560

113,969

112,178

86,801

82,596

79,981

71,014

58,718

Adjusted EBITDA(1)

9,458

7,720

16,287

7,869

5,569

4,883

4,116

4,466

Operational Information:

Vent Patients(2)

7,892

7,788

7,705

7,965

7,759

7,421

7,130

6,393

(1)Refer to "Non-GAAP Financial Measures" section above for definition of Adjusted EBITDA.

(2)Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.